Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CGP 19835; CGP 19835A; Junovan; L-MTP-PE; Liposomal MTP-PE; Mepact; MLV 19835A; MTP-PE; Muramyltripeptide phosphatidylethanolamine

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Medison Pharma; Takeda America Holdings
  • Class Antineoplastics; Drug conjugates; Ethanolamines; Immunoconjugates; Peptides
  • Mechanism of Action Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteosarcoma
  • Discontinued HIV infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 18 Apr 2017 Launched for Osteosarcoma (Non-metastatic) in Venezuela, South Korea, Ukraine, and Brazil (IV) before April 2017
  • 04 Nov 2016 University of Oxford completes the phase II MEMOS trial for Osteosarcoma (Metastatic disease, Second line therapy or greater) in Germany, Italy, Netherlands, Norway and United Kingdom (NCT02441309)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top